| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 14.7MM | - |
| Operating Income | -1.8MM | +79% |
| Operating Expenses | 16.6MM | - |
| Net Income | -2.7MM | +44% |
| R&D | 32K | - |
| G&A | 7MM | +83% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 26, 2024, according to a recent SEC Filing.
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 25, 2024, according to a recent SEC Filing.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript March 21, 2024 Fennec Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals’ Fourth Quarter and Full Year 2023 […]
Q4 2023 Fennec Pharmaceuticals Inc Earnings Call
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and Regulatory Milestones, and Tiered Royalties Up to the Mid-Twenties ~ ~ Pro forma fourth quarter cash in excess of $55 million ~ ~ Managemen
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detai
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors Fennec will receive €40 million in upfront and up to €210 million in additional commercial and regulatory milestones, and tiered royalties up to the mid-twenties Enhances Norgine’s commitment to bringing transformati